EUVIMEDEUVIMED entdecken
Crossref

Rethinking leflunomide in rheumatoid arthritis: Can innovative drug delivery approaches open new horizons?

Ashish Dhiman, Tejaswini Deshmukh, Kalpna Garkhal

Current Rheumatology Research · 24.12.2025 · 5 (1) · 27

DOI: 10.46439/rheumatology.5.032 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Rheumatology Research, online erschienen am 24.12.2025. Verfasst von Ashish Dhiman und 2 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Leflunomide (LEF) is one of the most effective synthetic disease-modifying antirheumatic drugs (DMARD) which is widely prescribed for rheumatoid arthritis. But the safety issues of LEF makes its use compromised due to various side effects like hepatotoxicity, GIT disturbances, etc, and variable patient responses. The longer retention period of LEF in body is another issue which requires the washout period of almost 2 weeks using cholestyramine or activated charcoal for complete removal from the body, hence, contraindicated in pregnant women. However, the arrival of biologics and targeted synthetic DMARDs have diminished the use of LEF, although, this molecule has excellent anti-arthritic potential with maximum efficacy. Recent progress in innovative and novel drug delivery strategies for RA have yielded promising outcomes, opening new horizons for safer delivery of LEF to RA patients. Approaches like polymeric, transdermal, and lipid-based nano-cargoes have shown potential in increasing efficacy, solubility and minimizing the systemic toxicity. Furthermore, combination of LEF with other DMARDs and stimuli-triggered drug release techniques could lead to the development of integrated modalities for LEF delivery in RA patients. Here, in this commentary, we believe that if safety and efficacy issues with LEF is successfully addressed to a significant extent using smart and innovative drug delivery approaches, the underutilization can be reduced and can open new avenues for safer LEF delivery in RA patients.

Zitieren

APA

Dhiman, A., Deshmukh, T., & Garkhal, K. (2025). Rethinking leflunomide in rheumatoid arthritis: Can innovative drug delivery approaches open new horizons?. Current Rheumatology Research, 5(1), 27. https://doi.org/10.46439/rheumatology.5.032

Vancouver

Dhiman A, Deshmukh T, Garkhal K. Rethinking leflunomide in rheumatoid arthritis: Can innovative drug delivery approaches open new horizons?. Current Rheumatology Research. 2025;5(1):27. doi:10.46439/rheumatology.5.032

BibTeX
@article{Dhiman2025,
  author = {Dhiman, Ashish and Deshmukh, Tejaswini and Garkhal, Kalpna},
  title = {Rethinking leflunomide in rheumatoid arthritis: Can innovative drug delivery approaches open new horizons?},
  journal = {Current Rheumatology Research},
  year = {2025},
  volume = {5},
  number = {1},
  pages = {27},
  doi = {10.46439/rheumatology.5.032}
}
Kostenlos starten →